Shareholder Rights Law Firm Johnson & Weaver, LLP is investigating whether members of the board of directors of Omnicare, Inc. (NYSE: OCR) breached their fiduciary duties in connection with the planned merger of the Company with CVS Health Corporation. Omnicare operates as a healthcare services company that specializes in the management of pharmaceutical care in the United States.

On May 21, 2015, Omnicare and CVS Health announced that they had entered into a definitive merger agreement. Under the terms of the agreement, Omnicare shareholders will receive $98.00 per share in cash for each common share held. The transaction is expected to close near the end of 2015, subject to regulatory approval.

The investigation concerns whether Omnicare’s board failed to satisfy their duties to the Company shareholders, including whether the board adequately pursued alternatives to the acquisition and whether the board obtained the best price possible for Omnicare’s shares of common stock. One Wall Street analyst has a $104.00 price target on Omnicare stock which is more than the $98.00 offer price.

If you are a shareholder of Omnicare and believe that the proposed buyout price is too low and you are interested in learning more about the investigation or your legal rights and remedies, please contact lead analyst Jim Baker (jimb@johnsonandweaver.com) at 619-814-4471.

About Johnson & Weaver, LLP:

Johnson & Weaver, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonandweaver.com. Attorney advertising. Past results do not guarantee future outcomes.

Johnson & Weaver, LLPJim Baker, 619-814-4471jimb@johnsonandweaver.com